Twenty-seven of 32 patients blinded by advanced dry age-related macular degeneration regained the ability to read after receiving a hair-thin photovoltaic chip placed beneath the retina, according to results from the PRIMAvera multicenter trial published in the New England Journal of Medicine in 2025. The PRIMA system, developed by Science Corporation, pairs a subretinal implant with infrared-projecting glasses to convert camera images into electrical signals that surviving retinal cells can interpret. For the millions of people living with geographic atrophy, a condition with no approved therapy that restores lost central vision, these 12-month results represent the first clinical evidence that a prosthetic device can deliver functional sight rather than simple light perception.
Why the PRIMA implant changes the calculus for geographic atrophy
Geographic atrophy destroys the photoreceptors at the center of the retina, erasing the sharp central vision people need for reading, recognizing faces, and driving. Existing treatments for dry AMD can slow the expansion of atrophic lesions, but none recover vision already lost. The PRIMAvera trial directly challenged that limitation. Designed as a single-arm, baseline-controlled study, it measured change in visual acuity at 6 and 12 months while patients used the PRIMA glasses compared with their performance without the device.
The results showed that the implant did not merely detect light. Patients achieved letter-score gains on standardized ETDRS charts sufficient to support form vision, the ability to distinguish shapes and text. An earlier first-in-human feasibility study involving five patients at a single center had already demonstrated that the PRIMA chip restored visual sensitivity within a former scotoma, the blind spot caused by atrophy, without degrading whatever natural peripheral acuity remained. That finding set the stage for the larger confirmatory trial, which expanded enrollment to 32 participants across multiple centers.
One hypothesis emerging from the combined data is that precise subretinal placement of the array, rather than patient baseline characteristics alone, may be the dominant predictor of clinically meaningful letter-score gains. The feasibility study flagged implant positioning as a key variable in early performance ranges. If that relationship holds across the full PRIMAvera cohort, it would mean surgical technique and postoperative imaging confirmation matter as much as patient selection, a distinction with direct consequences for how widely the technology could be deployed.
PRIMAvera trial data and what the numbers show
The core efficacy finding, that 27 of 32 patients regained reading ability at one year, was reported by Stanford Medicine in connection with the NEJM publication. That 84 percent response rate is unusually high for a retinal prosthesis trial. Previous devices aimed at inherited retinal diseases, such as the discontinued Argus II, produced far coarser visual output and rarely achieved reading-level acuity in recipients. In contrast, PRIMA’s design targets the macula directly, focusing stimulation on the region responsible for detailed central vision.
The PRIMA chip itself is thinner than a human hair and operates without any external power cable. Infrared light projected by the glasses activates photovoltaic pixels on the implant, which in turn stimulate the bipolar and ganglion cells that survive even after photoreceptors die. Because the device uses incident light rather than wired power, surgeons can place it fully under the retina without a trans-scleral connector, reducing the risk of infection and mechanical failure at the entry site. Science Corporation characterized the device as restoring functional central vision in patients with geographic atrophy caused by AMD, emphasizing that patients were able to read high-contrast text and identify letters within the stimulated visual field.
Safety data from the trial and from earlier feasibility work identified ocular hypertension and macular holes among the reported adverse events, according to full-text clinical reporting on the PRIMA platform. Most complications were managed with standard ophthalmic interventions, but a subset required additional surgery, underscoring that the procedure is not risk-free. Postmortem histological analysis of eyes from deceased PRIMAvera participants found limited inflammation and stable tissue integration around the implant, suggesting the device does not provoke a destructive immune response in the short term. Those pathology findings, however, come from a small number of cases and do not yet address what happens over years of continuous use.
Another key question is how well patients can integrate prosthetic central vision with their remaining natural peripheral vision in daily life. Trial assessments relied on standardized reading charts and controlled laboratory tasks. Early qualitative reports indicate that patients needed training to align the camera view in the glasses with the location of the implant and to adapt to the artificial contrast and resolution of the projected image. Some participants described the prosthetic vision as pixelated but nonetheless sufficient for reading large print and recognizing simple shapes. How those experiences translate into real-world independence-navigating unfamiliar environments, managing medication labels, or using digital devices-will require longer follow-up and more granular functional outcome measures.
Gaps in the evidence and what patients should watch for next
The strongest limitation of the current data is its 12-month horizon. Whether the PRIMA implant continues to deliver stable letter-score gains at two, five, or ten years is unknown. Retinal prostheses face degradation risks from both the biological environment, where encapsulation tissue can grow over the device, and from the electronics themselves, which can fail under chronic exposure to intraocular fluid. The histological evidence so far is encouraging but drawn from too few cases to project long-term durability with confidence.
Full per-patient visual acuity trajectories and detailed adverse event timelines have not been posted in the ClinicalTrials.gov registry entry for PRIMAvera. The published NEJM results and institutional releases provide aggregated summaries, but independent researchers cannot yet replicate the responder analysis or verify how the threshold for clinically meaningful improvement was defined. Science Corporation has described a threshold of 10 or more ETDRS letters gained, a commonly used benchmark in ophthalmology, but that cutoff has not been explicitly confirmed through the primary trial registry or shared patient-level data.
Regulatory status is another open question. The PRIMA system has not received FDA clearance or broad marketing authorization in major jurisdictions, and the NEJM report describes the device within the context of an investigational study rather than an approved therapy. Any eventual submission will have to address not only efficacy and safety but also manufacturing consistency, device longevity, and the learning curve for surgeons and rehabilitation specialists. Payers will likely demand evidence that the gains in reading and form vision translate into measurable improvements in quality of life and reductions in disability-related costs.
For patients and clinicians, several milestones will be worth tracking over the next few years. Longer-term follow-up from the PRIMAvera cohort should clarify whether performance plateaus, improves with training, or declines as the implant ages. Additional trials may explore optimized surgical placement, refined image-processing algorithms in the glasses, or combination approaches that pair PRIMA with therapies aimed at slowing further atrophy. Independent groups will also need access to anonymized data sets to validate the reported response rates and to probe which baseline factors-such as lesion size, residual inner retinal integrity, or fixation stability-best predict success.
Even with these uncertainties, the PRIMAvera results mark a turning point in how researchers think about dry AMD. For decades, geographic atrophy was framed as an inexorable loss: once photoreceptors died, central vision was considered irretrievable. By demonstrating that surviving inner retinal circuitry can be reactivated with a photovoltaic array to restore reading-level acuity in most participants, PRIMA challenges that assumption. The technology is still experimental, and it will not restore vision to normal or eliminate the need for magnification, training, and support. But it offers a concrete proof of concept that prosthetic central vision for dry AMD is technically feasible.
Whether that promise becomes a widely available option will depend on rigorous long-term data, transparent reporting, and careful integration into clinical practice. For now, patients with geographic atrophy can view PRIMA as a hopeful but still investigational avenue-one that shifts the conversation from merely slowing vision loss to the possibility of regaining some of what has already been lost.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
